LYRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. LYRA has a bad profitability rating. Also its financial health evaluation is rather negative. LYRA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year LYRA has reported negative net income.
In the past year LYRA has reported a negative cash flow from operations.
LYRA had negative earnings in each of the past 5 years.
LYRA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

LYRA has a Return On Assets of -75.38%. This is in the lower half of the industry: LYRA underperforms 72.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	-75.38%
ROE	N/A
ROIC	N/A

ROA(3y)-78.35%

ROA(5y)-68.36%

ROE(3y)-314.8%

ROE(5y)-220.22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LYRA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LYRA has more shares outstanding
LYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -15.69, we must say that LYRA is in the distress zone and has some risk of bankruptcy.
LYRA has a Altman-Z score of -15.69. This is amonst the worse of the industry: LYRA underperforms 80.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-15.69

ROIC/WACCN/A

WACC9.37%

2.3 Liquidity

LYRA has a Current Ratio of 2.43. This indicates that LYRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.43, LYRA is in line with its industry, outperforming 44.74% of the companies in the same industry.
A Quick Ratio of 2.43 indicates that LYRA has no problem at all paying its short term obligations.
LYRA has a Quick ratio (2.43) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.43
Quick Ratio	2.43

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LYRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.28%, which is quite impressive.
The Revenue for LYRA has decreased by -59.21% in the past year. This is quite bad
Measured over the past years, LYRA shows a very strong growth in Revenue. The Revenue has been growing by 74.24% on average per year.

EPS 1Y (TTM)69.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%62.44%

Revenue 1Y (TTM)-59.21%

Revenue growth 3Y74.24%

Revenue growth 5YN/A

Sales Q2Q%-87.18%

3.2 Future

The Earnings Per Share is expected to grow by 14.65% on average over the next years. This is quite good.
Based on estimates for the next years, LYRA will show a very strong growth in Revenue. The Revenue will grow by 111.38% on average per year.

EPS Next Y63.39%

EPS Next 2Y37.84%

EPS Next 3Y24.06%

EPS Next 5Y14.65%

Revenue Next Year-57.6%

Revenue Next 2Y5.63%

Revenue Next 3Y95.96%

Revenue Next 5Y111.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LYRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYRA. No positive earnings are expected for the next year.